Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
Contract Revenue $ 1,096
Costs and Expenses:    
Research and development 11,433 14,489
General and administrative 8,729 10,373
Impairment charges of goodwill and other intangible assets 2,093
Impairment charges of other assets 2,338
Total costs and expenses 24,593 24,862
Loss from operations (24,593) (23,766)
Sale of New Jersey net operating loss & tax credits 484
Other income, net 262 340
Loss before tax (24,331) (22,942)
Income tax benefit 80
Net loss $ (24,251) $ (22,942)
Net loss per share - basic $ (4.98) $ (5.28)
Net loss per share - diluted $ (4.98) $ (5.28)
Weighted average common shares outstanding:    
Basic 4,865,829 4,345,291
Diluted 4,865,829 4,345,291
Other comprehensive gain, net of tax    
Unrealized gain on securities available-for-sale $ 221 $ 603
Other comprehensive gain, net of tax 221 603
Comprehensive loss $ (24,030) $ (22,339)